Biograil key facts
as of Oct 2026- Developer of a medical device designed to replace the standard injection system of medicines.
- Biograil is valued at approximately $31.5M as of Oct 2026 (last reported valuation).
- It has raised $21.1M; the latest was Later Stage VC ($11.2M) in Dec 2025.
- Notable investors include High-Tech Gründerfonds, Kinled Holding, Verve Ventures, Evonik Venture Capital, Sanner Ventures — 11 tracked in total.
- Status: Privately Held (backing).
Biograil's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Biograil: the Monday email on marks, rounds and moves
Biograil funding rounds
No funding rounds for Biograil are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Biograil
11+Membership and data by Private Market View
Biograil valuation
Biograil's last reported valuation was $31.5 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
Biograil investors
11 investors are on record for Biograil, including High-Tech Gründerfonds, Kinled Holding, Verve Ventures and Evonik Venture Capital.
About Biograil
Developer of a medical device designed to replace the standard injection system of medicines. The company's device is based upon an injection molding technique and uses the body's peristaltic forces to facilitate the delivery of the biologic efficiently into the gastrointestinal wall, enabling patients to receive medicines painlessly.
- Sector
- Healthcare
- HQ
- Roskilde, Denmark
- Founded
- 2019
- Employees
- 28
- Website
- biograil.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.